Haemate

Haemate is a prescription injectable solution that contains human coagulation factor VIII and von Willebrand factor to replace deficient clotting proteins in patients with hemophilia A and von Willebrand disease. Administered intravenously, it is manufactured in the European Union and supplied in a sterile vial for single‑use infusion. The formulation aims to rapidly restore the intrinsic coagulation pathway and support hemostasis during bleeding episodes or before surgery.

Haemate is indicated for the management of bleeding disorders related to factor VIII and von Willebrand factor deficiencies.

- Treatment of acute bleeding episodes in patients with hemophilia A (factor VIII deficiency). - Prophylactic replacement therapy to prevent spontaneous or trauma‑induced bleeds in hemophilia A. - Management of bleeding and surgical prophylaxis in patients with von Willebrand disease, particularly type 3. - Support during major surgery or invasive procedures in individuals with combined factor VIII/vWF deficiency. - Adjunct therapy in patients undergoing dental extractions or minor procedures when hemostasis is required.

The safety profile of Haemate includes both frequently observed reactions and rare but serious events.

Common: - Mild infusion‑site reactions such as erythema, swelling, or pain. - Transient fever or chills during or shortly after administration. - Headache or fatigue.

Serious: - Allergic anaphylactic reactions, including urticaria, bronchospasm, or hypotension. - Development of inhibitors (antibodies) against factor VIII or von Willebrand factor. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.

Clinicians should consider several precautions when prescribing Haemate to ensure safe and effective use.

- Assess baseline factor VIII and von Willebrand activity levels before initiating therapy. - Monitor for the development of inhibitors, especially in previously untreated patients. - Use caution in patients with a history of allergic reactions to plasma‑derived products. - Avoid rapid infusion rates; administer according to recommended infusion guidelines to reduce adverse reactions. - Evaluate cardiovascular risk, as rapid correction of coagulation may increase thrombosis risk. - Pregnancy and lactation status should be reviewed, as safety data are limited. - Renal or hepatic impairment may affect clearance; adjust dosing as clinically indicated.

Haemate may interact with other medications that affect hemostasis or immune response.

Avoid: - Concurrent use of other pro‑coagulant agents (e.g., activated factor VII) without specialist guidance. - Administration with investigational gene‑therapy products targeting factor VIII.

Use with caution: - Antifibrinolytic agents such as tranexamic acid may augment hemostatic effect; monitor for thrombosis. - Immunosuppressive drugs (e.g., rituximab) may alter inhibitor development risk. - Concomitant use of high‑dose steroids may mask allergic reactions. - Vaccines administered shortly after infusion may have reduced efficacy; schedule appropriately.